NAMS ▲ +4.0% - NewAmsterdam Pharma Company N.V. $NAMS reported Q3 2026 EPS of -$0.14, beating the -$0.45 estimate by 68.9%. Revenue of $19.2M beat the $7.4M estimate by 158.4%. 04-NOV-2026 07:40 AM ET